DelveInsight’s, “Opioid Dependence Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the Opiod Dependence pipeline drug profiles, including Opiod Dependence clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Opiod Dependence Emerging drugs, the Opiod Dependence pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Opiod Dependence pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Opiod Dependence Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Opiod Dependence clinical trials studies, Opiod Dependence NDA approvals (if any), and product development activities comprising the technology, Opiod Dependence collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Opiod Dependence Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Opiod Dependence Pipeline landscape @ Opiod Dependence Pipeline Outlook Report
Opiod Dependence Overview
Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States.
Recent Developmental Activities in the Opiod Dependence Treatment Landscape
For further information, refer to the detailed Opiod Dependence Drugs Launch, Opiod Dependence Developmental Activities, and Opiod Dependence News, click here for Opiod Dependence Ongoing Clinical Trial Analysis
Opiod Dependence Emerging Drugs Profile
Zolunicant (MM-110) is a α3β4 nicotinic cholinergic receptor antagonist that offers a novel mechanism to address a critical gap in current opioid use disorder treatment. Positive safety and tolerability results support the advancement of MM-110 and guide the Phase IIa dose design in individuals undergoing supervised opioid withdrawal. Phase IIa trial remains on track to initiate in Q2 2022.
KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 is atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.
Opiod Dependence Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies Opioid Dependence. The companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e phase III include Opiant Pharmaceuticals
Find out more about the Opiod Dependence Pipeline Segmentation, Therapeutics Assessment, and Opiod Dependence Emerging Drugs @ Opiod Dependence Treatment Landscape
Scope of the Opiod Dependence Pipeline Report
Dive deep into rich insights for drugs for Opiod Dependence Pipeline Companies and Therapies, click here @ Opiod Dependence Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Opiod Dependence Mergers and acquisitions, Opiod Dependence Licensing Activities @ Opiod Dependence Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/